Taysha Gene Therapies Common Stock Net 2020-2024 | TSHA
Taysha Gene Therapies common stock net from 2020 to 2024. Common stock net can be defined as the value of common equity ownership.
Taysha Gene Therapies Annual Common Stock Net
(Millions of US $) |
| 2023 |
$0 |
| 2022 |
$0 |
| 2021 |
$ |
| 2020 |
$ |
| 2019 |
$ |
Taysha Gene Therapies Quarterly Common Stock Net
(Millions of US $) |
| 2024-09-30 |
$0 |
| 2024-06-30 |
$0 |
| 2024-03-31 |
$0 |
| 2023-12-31 |
$0 |
| 2023-09-30 |
$0 |
| 2023-06-30 |
$0 |
| 2023-03-31 |
$0 |
| 2022-12-31 |
$0 |
| 2022-09-30 |
$0 |
| 2022-06-30 |
$0 |
| 2022-03-31 |
|
| 2021-12-31 |
|
| 2021-09-30 |
|
| 2021-06-30 |
|
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
$0 |
| 2020-03-31 |
$0 |
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.434B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
